Publications

March 1993 (Revised May 1998)
Teaching Note

ImmuLogic Pharmaceutical Corporation (Series) TN

Teaching Note for (9-293-066--071) and (9-293-087). View Details

Keywords: Pharmaceutical Industry

March 1993
Supplement

Burroughs Wellcome and AZT (B)

By: Willis M. Emmons III

Describes Burroughs Wellcome's response to protests over the pricing of its AIDS drug AZT in September 1989. Also presents short-term reactions by government officials, AIDS activists, and investors to Burroughs Wellcome's strategy. View Details

Keywords: Ethics; Health Pandemics; Multinational Firms and Management; Price; Crime and Corruption; Risk and Uncertainty; Business Strategy; Business and Community Relations; Business and Government Relations; Business and Shareholder Relations; Pharmaceutical Industry

March 1993
Supplement

Burroughs Wellcome and AZT (C)

By: Willis M. Emmons III

Describes key developments relating to Burroughs Wellcome, AZT and other AIDS drugs, and the AIDS issue in general from late 1989 through 1992. Includes excerpts from Wellcome PLC's financial statements and updated statistics on AIDS in the United States. View Details

Keywords: Health Pandemics; Multinational Firms and Management; Financial Statements; Pharmaceutical Industry; United States

February 1993 (Revised August 1995)
Case

Medicare Payment for Drugs and Medical Devices

By: Regina E. Herzlinger

Keywords: Health Care and Treatment; Business and Government Relations; Medical Devices and Supplies Industry; Medical Devices and Supplies Industry; Medical Devices and Supplies Industry

Find at Harvard

January 1993 (Revised November 1993)
Case

Warner-Lambert Ireland: Niconil

By: John A. Quelch and Susan Smith

The marketing director of Warner-Lambert's Irish subsidiary is completing the marketing plan for the launch of Niconil, a transdermal skin patch to facilitate smoking cessation. View Details

Keywords: Product Launch; Marketing Strategy; Pharmaceutical Industry; Republic of Ireland

January 1993 (Revised April 1993)
Case

Chadwick, Inc.: The Balanced Scorecard

By: Robert S. Kaplan

The pharmaceutical division of a diversified company has been asked to develop a Balanced Scorecard. Research and development projects take about ten years to bring a new product to the marketplace and the division depends on good relations and active feedback from its... View Details

Keywords: Balanced Scorecard; Performance Evaluation; Customer Relationship Management; Goals and Objectives; Customer Satisfaction; Research and Development; Marketplace Matching; Financial Condition; Product Launch; Pharmaceutical Industry

December 1992 (Revised September 1996)
Case

ImmuLogic Pharmaceutical Corporation (Abridged)

ImmuLogic Pharmaceutical Corp., a development-stage biotechnology company, is considering making an initial offering of common stock. The rationales for and problems of high-technology start-ups are explored. The challenges posed by "windows" for public offerings are... View Details

Keywords: Decisions; Initial Public Offering; Entrepreneurship; Going Public; Business Startups; Biotechnology Industry; Biotechnology Industry; United States

October 1992 (Revised September 1993)
Case

Nopane Advertising Strategy

By: David E. Bell

Nopane is a proprietary drug that sells in much of the United States. It faces substantial competition. The brand manager is undertaking an experiment to determine whether ad copy should be emotional-based or rational-based. The data and associated regression results... View Details

Keywords: Competition; Intellectual Property; Advertising; Health Care and Treatment; Brands and Branding; Product Marketing; Pharmaceutical Industry; United States

October 1992 (Revised November 1997)
Case

ImmuLogic Pharmaceutical Corporation (A): March 1991

ImmuLogic Pharmaceutical Corp., a development-stage biotechnology company, is considering making an initial offering of common stock. The diverse perspectives of the entrepreneur, venture capitalist, investment banker, and institutional investor are explored. Problems... View Details

Keywords: Decisions; Entrepreneurship; Venture Capital; Banks and Banking; Initial Public Offering; Going Public; Perspective; Valuation; Biotechnology Industry; Biotechnology Industry

October 1992 (Revised March 1993)
Supplement

ImmuLogic Pharmaceutical Corporation (B1): Malcolm Gefter

Supplements the (A) case. View Details

Keywords: Pharmaceutical Industry

October 1992 (Revised April 1993)
Supplement

ImmuLogic Pharmaceutical Corporation (B2): Henry McCance

Supplements the (A) case. View Details

Keywords: Pharmaceutical Industry

October 1992 (Revised March 1993)
Supplement

ImmuLogic Pharmaceutical Corporation (B3): Katherine Kirk

Supplements the (A) case. View Details

Keywords: Pharmaceutical Industry

October 1992 (Revised April 1993)
Supplement

ImmuLogic Pharmaceutical Corporation (B4): Phillip Gross

Supplements the (A) case. View Details

Keywords: Pharmaceutical Industry

October 1992 (Revised March 1993)
Supplement

ImmuLogic Pharmaceutical Corporation (C): April 1991

Supplements the (A) case. View Details

Keywords: Pharmaceutical Industry

June 1992
Teaching Note

Novel Combination of Two Drugs (B) and (C) and Technology Transfer Anti-Inflammatory Drug (B) and (C), Teaching Note

By: Regina E. Herzlinger

Keywords: Innovation and Invention; Technology; Pharmaceutical Industry

May 1992
Teaching Note

Amgen, Inc.: Planning the Unplannable, Teaching Note

By: Nitin Nohria

Teaching Note for (9-492-052). View Details

Keywords: Pharmaceutical Industry

May 1992
Teaching Note

RU 486 (A) and (B), Teaching Note

By: Joseph L. Badaracco Jr.

Teaching Note for (9-391-050) and (9-391-051). View Details

Keywords: Pharmaceutical Industry; Pharmaceutical Industry; France; Germany; United States

March 1992
Case

Amgen, Inc.: Planning the Unplannable

By: Nitin Nohria

By the early 1990s, Amgen--a pharmaceutical company started little over a decade ago as Applied Molecular Genetics--was within range of becoming a billion-dollar company. With two extremely successful biotechnology drugs on the market, Amgen stood as the largest and... View Details

Keywords: Growth and Development Strategy; Strategic Planning; Success; Risk and Uncertainty; Pharmaceutical Industry

February 1992 (Revised April 1995)
Case

Pfizer: Global Protection of Intellectual Property

By: Lynn S. Paine and Michael Santoro

Top officials at Pfizer are assessing their strategy for improving protection of Pfizer's patents around the world. The outcome of the Uruguay Round of the GATT negotiations is uncertain, and it is not clear whether an acceptable intellectual property protection... View Details

Keywords: Patents; Trade; Policy; Government and Politics; Business Strategy; Agreements and Arrangements; Alliances; Cross-Cultural and Cross-Border Issues; Pharmaceutical Industry; United States; Japan; Europe